Recently, it has been reported that a combination of anti-PD-1 and anti-TIGIT antibodies remarkably restored the function of tumor antigen-specific CD8+ T cells, illustrating the significance of PD-1 and TIGIT on CD8+ T cells and the interactions of these receptors with their ligands on APCs and cancer cells [31]. Here, TIGIT is linked to cancer.